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Summary: Antidotes for the treatment of human poisoning are 
rare but essential medicines. Their provision is a particular chal-
lenge because their availability is limited, and many products are not 
authorized by the government. Their distribution may need special 
logistic efforts, and their clinical use is difficult because physicians 
are often not familiar with the indications, ways of administration, 
specific precautions, and adverse effects. Therefore, the provision 
of antidotes requires specific expertise, which is usually present in 
poison center specialists.
In Switzerland, the supply of antidotes is standardized. The anti-
dotes are classified in 3 complementary assortments based on the fre-
quency of poisoning, the place of administration, and logistic criteria. 
There is a small decentralized assortment for high street pharmacies, 
an assortment for hospitals with emergency departments, and an 
assortment for regional centers specialized in antidote supply. In addi-
tion to these, there are a number of special assortments: the antidotes 
stocked in the Swiss Military Pharmacy and in specialized decon-
tamination hospitals for mass casualties, the antivenins for exotic 
snake bites (antivenin.ch), antidotes for radionuclides, and antidotes 
for prehospital emergency medical services (“Swiss ToxBox”). All 
assortments are described in the Swiss Antidotes List.
The antidote network is managed by a working group of hos-
pital pharmacists and staff of the STIC on behalf of the cantons. 
The group updates and publishes the Swiss Antidotes List annually 
(www.antidota.ch).
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Summary: The re-evaluation of the benefit/risk balance of a medi-
cal product as negative often triggers a scandal. The public outrage 
focuses usually on drug companies, portrayed as cynical and greedy, 
and regulatory agencies, considered as incompetent. The agencies 
should have known! Curiously, the attention of the public focuses 
on efficacy only at the beginning of a product life and turns to a 
safety-first attitude later, when doubts arise. This illustrates a lack 
of appreciation of the risk/benefit balance concept in our society, 
although life is an everlasting risk/benefit game. Most people tend 
to consider the risk/benefit balance of a medication to be established 
once and for all at the time of registration. In fact, clinical develop-
ment favors the evaluation of efficacy, represented by well-defined, 
prospectively sought end points, assessed with sufficient power, with 
a predefined statistical risk. In contrast, safety assessment is based 
on the reporting of mostly unknown events, with a very low power 
and a high risk of multiplicity. Given these uncertainties, changes in 
the benefit/risk balance after some time of marketing are not surpris-
ing. Such changes may occur with increasing treatment duration or 
simply with accumulation of data. Once a safety problem has been 
identified, it is necessary to confront the newly discovered risk with 
the already-established benefit. This is relatively easy if the benefit 
was assessed on hard, clinically relevant end points. However, when 
the benefit was assessed on intermediary or surrogate end points, it 
does not weigh much against toxicity. In the case of pioglitazone, 
the decrease in HbA1C accepted as a proof of efficacy did not stand 
the comparison with a modest increase in the risk of bladder cancer 
for the French Agency, who suspended the drug marketing authori-
zation. The EMA and the FDA said the drug may prove useful for 
some patient populations, without defining them. This points to a 
lack of an evidence-based method of assessment of the benefit/risk 
balance. Finally, the understanding of the benefit/risk balance varies 
according to the disease. Cancer is a disease for which there is a high 
tolerance to safety issues. Some cancer treatments are approved that 
give a very small increase in survival at the expense of a tremendous 
increase in grade III to IV toxicity. While some patients may put a 
very high price on living a few weeks more, a favorable benefit/risk 
balance for many others is doubtful. In conclusion, the benefit/risk 
assessment may be improved by a more extensive use of clinically 
relevant, patient-centered efficacy end points, early use of pharma-
coepidemiologic studies in the risk-management plans, and modeling 
to refine the approach for subpopulations. An effort to educate the 
public about the risk/benefit issues is necessary, with more objective 
information in the prescribing information and patient leaflet.
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Summary: There is scientific evidence about the existence of intereth-
nic differences in the metabolism and response to some drugs. The 
guidelines and dosage recommendations are not necessarily the 
most appropriate/accurate for populations with different ethnic 
backgrounds. As a result, there appears to be patients who do not 
respond to standard pharmacologic treatments designed for other 
populations or who present adverse drug reactions. These pharma-
cologic therapeutic failures may be related to genetic differences in 
the drug metabolism or to other factors linked to the drug mechanism 
of action.
Genetic factors may underlie individual susceptibility to some 
types of adverse drug reactions (ADRs). The ability to identify indi-
viduals who are susceptible to ADRs has the potential to reduce 
the personal harm and economic costs of drug-related morbidity. 
Information from these efforts could be usefully exploited for bet-
ter disease management and for minimizing harms from ADRs. 
Information about ethnic specificity of ADR-genetic biomarkers 
may help to improve the pharmacovigilance strategies in a given 
population.
In sum, pharmacogenetic studies may help pharmacovigilance, 
adapting therapeutic recommendations to each country, based on the 
specific ethnic and cultural identities. This has represented the main 
goal of the RIBEF Pharmacogenetic Iberoamerican Network, which 
gathers investigators and clinicians from all over Latin America and 
some European countries. The RIBEF strategy claims the necessity of 
developing regional or local strategies to improve the pharmacologic 
treatment’s benefit/risk relationship by developing studies specifically 
in indigenous and Latino Mestizo populations. Population-oriented 
pharmacogenetics might enhance global drug use policy and phar-
macovigilance at country level according to the ethnical background 
and cultural specificity, and has a strong potential to improve drug 
use in populations neglected in clinical trials.
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